RT @sciRPatel: Fun collaboration with Dr. Wang and Dr. Blaser on studying immunologic and molecular signatures during AML treatment - my fi…
#ICYMI: Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis by Charalambos Andreadis, Victoria E. Wang and colleagues @UCSFDOM. https://t.co/RcG9Ks7oWO https://t.
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis https://t.co/EPXEUDFIvC
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes… https://t.co/GKxpNCSFIQ
Great to read the results of this new clinical trial! Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis https://t.co/aWSfX0DSoi
New article: Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis https://t.co/ufwQh4Qa2J #AML #leusm #hematology https://t.co/PVpFZmOdFY
From the September issue— Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory #AML: Clinical Outcomes and High-Dimensional Analysis. https://t.co/PdGkUJ7bEl https://t.co/dN4ASIHylq
HAEM: inhibition of MET signalling with an anti-HGF antibody (ficlatuzumab) combined with aca-C delivered complete response rate of 57% in high risk relapsed/refractory acute myeloid leukaemia in a small (n=17) phase 1b study. https://t.co/aGolvIY4Pp
RT @_TanyaBondar_: Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia The first clinical trial publ…
Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia The first clinical trial published in @BCD_AACR is getting noticed in the medical news Article: https://t.co/yqE45iiJmb https://t.co/bZmOmFO4Zf
RT @sciRPatel: Fun collaboration with Dr. Wang and Dr. Blaser on studying immunologic and molecular signatures during AML treatment - my fi…
💊 This #ClinicalTrial led by Dr. Charalambos Andreadis @UCSF evaluated ficlatuzumab, an anti-HGF antibody, in combination with cytarabine in #AML patients. Among 17 evaluable patients, the overall response rate was 53%, all complete remissions. 📎 https://
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @sciRPatel: Fun collaboration with Dr. Wang and Dr. Blaser on studying immunologic and molecular signatures during AML treatment - my fi…
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @sciRPatel: Fun collaboration with Dr. Wang and Dr. Blaser on studying immunologic and molecular signatures during AML treatment - my fi…
RT @sciRPatel: Fun collaboration with Dr. Wang and Dr. Blaser on studying immunologic and molecular signatures during AML treatment - my fi…
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @BCD_AACR: Read the study: https://t.co/X6WM1cgT2r https://t.co/40tccejaEM
Fun collaboration with Dr. Wang and Dr. Blaser on studying immunologic and molecular signatures during AML treatment - my first paper from UCSF. Thanks to @Arrkal and @GabiFragiadakis for this opportunity! https://t.co/Fx2DGbNVVT
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
RT @RahulBanerjeeMD: When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFC…
When cytarabine MET refractory AML 👇 Great work in @BCD_AACR by @AndreadisBabis , @ROlinMD , @hemedoc et al at @UCSFCancer. Ph1 study: rather than doubling down on anthracyclines /mitoxantrone in 1° AML induction failure, MET signaling blockade + AraC ha
Read the study: https://t.co/X6WM1cgT2r